COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance
Written by
Neurology Live
Published
0
comments
0
min
The FDA has accepted the IND for COYA 302, a Treg-targeting combination therapy for ALS, clearing the way for a pivotal phase 2 multicenter trial.